Log in
(Ad)
If you're happy with stocks yielding you 4% or 5% a year, you don't need this. But if you want to see how we built a portfolio that now pays us a 67% cash on cash return - with no leverage, options, or gimmicks.

NYSE:NVO - Novo Nordisk A/S Stock Price, Forecast & News

$61.32
+0.18 (+0.29 %)
(As of 01/23/2020 08:00 AM ET)
Today's Range
$61.08
Now: $61.32
$61.65
50-Day Range
$56.53
MA: $58.24
$62.39
52-Week Range
$46.10
Now: $61.32
$62.69
Volume1.22 million shs
Average Volume1.04 million shs
Market Capitalization$145.21 billion
P/E Ratio25.03
Dividend Yield1.04%
Beta0.6
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone45-4444-8888

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.72 billion
Cash Flow$2.76 per share
Book Value$3.24 per share

Profitability

Net Income$5.91 billion

Miscellaneous

Employees43,202
Outstanding Shares2,368,000,000
Market Cap$145.21 billion
Next Earnings Date2/7/2020 (Estimated)
OptionableOptionable

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

Join a small community of investors looking for the next big winner. Every Sunday reveals 3 compelling stocks that should be on your radar for the week ahead. Sign up here to see what stocks have made it to our watchlist this week.

Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S announced a Semi-Annual dividend on Friday, August 9th. Investors of record on Monday, August 19th will be given a dividend of $0.318 per share on Tuesday, August 27th. The ex-dividend date is Friday, August 16th. View Novo Nordisk A/S's Dividend History.

How will Novo Nordisk A/S's stock buyback program work?

Novo Nordisk A/S announced that its Board of Directors has authorized a stock buyback program on Friday, February 2nd 2018, which allows the company to buyback shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company's board believes its shares are undervalued.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) announced its quarterly earnings results on Friday, November, 1st. The company reported $0.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.62 by $0.02. The company earned $4.51 billion during the quarter, compared to analysts' expectations of $4.55 billion. Novo Nordisk A/S had a return on equity of 75.48% and a net margin of 32.44%. View Novo Nordisk A/S's Earnings History.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Friday, February 7th 2020. View Earnings Estimates for Novo Nordisk A/S.

What price target have analysts set for NVO?

12 brokers have issued 12-month price objectives for Novo Nordisk A/S's shares. Their forecasts range from $48.61 to $400.00. On average, they anticipate Novo Nordisk A/S's share price to reach $181.58 in the next twelve months. This suggests a possible upside of 196.1% from the stock's current price. View Analyst Price Targets for Novo Nordisk A/S.

What is the consensus analysts' recommendation for Novo Nordisk A/S?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 1 sell rating, 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novo Nordisk A/S.

Has Novo Nordisk A/S been receiving favorable news coverage?

News headlines about NVO stock have been trending somewhat negative this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novo Nordisk A/S earned a news impact score of -1.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the company's share price in the next several days. View News Stories for Novo Nordisk A/S.

Who are some of Novo Nordisk A/S's key competitors?

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Johnson & Johnson (JNJ), AT&T (T), NVIDIA (NVDA), Starbucks (SBUX), Cisco Systems (CSCO) and Alibaba Group (BABA).

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the folowing people:
  • Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 53)
  • Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 59)
  • Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 47)
  • Mr. Lars Green, Exec. VP and Head of Bus. Services & Compliance (Age 52)
  • Mr. Ole F. Ramsby, Sr. VP & Gen. Counsel of Legal Affairs

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.01%), Janney Montgomery Scott LLC (0.00%), Atwater Malick LLC (0.00%), Commerzbank Aktiengesellschaft FI (0.00%), Smithbridge Asset Management Inc. DE (0.00%) and Brookmont Capital Management (0.00%). View Institutional Ownership Trends for Novo Nordisk A/S.

Which institutional investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Commerzbank Aktiengesellschaft FI, First Hawaiian Bank, Scout Investments Inc., Norris Perne & French LLP MI, Smithbridge Asset Management Inc. DE, Brookmont Capital Management and Norman Fields Gottscho Capital Management LLC. View Insider Buying and Selling for Novo Nordisk A/S.

Which institutional investors are buying Novo Nordisk A/S stock?

NVO stock was bought by a variety of institutional investors in the last quarter, including Chemung Canal Trust Co., Janney Montgomery Scott LLC, We Are One Seven LLC, Calamos Advisors LLC, Ingalls & Snyder LLC, SeaCrest Wealth Management LLC, Atwater Malick LLC and Huntington National Bank. View Insider Buying and Selling for Novo Nordisk A/S.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $61.32.

How big of a company is Novo Nordisk A/S?

Novo Nordisk A/S has a market capitalization of $145.21 billion and generates $17.72 billion in revenue each year. The company earns $5.91 billion in net income (profit) each year or $2.52 on an earnings per share basis. Novo Nordisk A/S employs 43,202 workers across the globe.View Additional Information About Novo Nordisk A/S.

What is Novo Nordisk A/S's official website?

The official website for Novo Nordisk A/S is http://www.novonordisk.com/.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]


MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  331 (Vote Outperform)
Underperform Votes:  434 (Vote Underperform)
Total Votes:  765
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe NVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel